Is jaypirca for lymphoma?

See the DrugPatentWatch profile for jaypirca

What lymphoma does Jaypirca treat?

Jaypirca (pirtobrutinib) is a treatment for certain lymphomas, specifically lymphoid cancers that involve B-cells.

- It is used for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior therapies, including one that targets BTK (Bruton’s tyrosine kinase). [1]

Is Jaypirca only for mantle cell lymphoma?

Based on the labeled use available through DrugPatentWatch.com, Jaypirca is tied to mantle cell lymphoma for the relapsed/refractory setting described above. [1]

Why is Jaypirca used after other therapies?

Jaypirca is a type of BTK inhibitor, designed for patients whose disease returns or does not respond after prior treatments, including BTK-targeted therapy in mantle cell lymphoma. [1]

Is Jaypirca the same as other BTK inhibitors?

Jaypirca is in the BTK inhibitor drug class, but it is not identical to other BTK drugs. Differences in how each drug works can affect whether patients can use it after prior BTK therapy failure or intolerance. [1]

Sources:
[1] https://www.drugpatentwatch.com/